Alx Oncology Holdings FY 2020: revenue $1.2M; diluted EPS −$2.76
- Form
- 10-K
- Filed
- Period
- Importance
- Notable
- Accession
- 0001564590-21-014169
Key figures from this report
These are the numbers Alx Oncology Holdings reported for the year ended Dec 31, 2020, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.
- Revenue$1.2MNo year-earlier figure tagged10-K income statement, on EDGAR
- Net income−$45.7MNo year-earlier figure tagged10-K income statement, on EDGAR
- Diluted EPS−$2.76No year-earlier figure tagged10-K income statement, on EDGAR
- Cash and cash equivalents$434.2MNo year-earlier figure tagged10-K balance sheet, on EDGAR
- Cash from operations−$38.3MNo year-earlier figure tagged10-K cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Charlie's Holdings CHUC public float $18M, Jun 30, 2025
- Cognition Therapeutics CGTX public float $18M, Jun 30, 2025
- IGC Pharma IGC public float $18M, Jun 30, 2025
- Ernexa Therapeutics ERNA public float $18M, Jun 30, 2025
- Marker Therapeutics MRKR public float $17M, Jun 30, 2025